|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> p16 play an unique role in lung cancer survival.
|
31157548 |
2019 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> p16 play an unique role in lung cancer survival.
|
31157548 |
2019 |
|
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> p16 play an unique role in lung cancer survival.
|
31157548 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusions:</b> HCC pathogenesis affecting p16 methylation don't work during normal blood, when from benign diseases to HCC bloods, can produce powerful role.
|
29896276 |
2018 |
|
Squamous cell carcinoma of esophagus
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
<b>CONCLUSIONS:</b> These results suggest that hr-HPV types are not associated with the development of ESCC and that p53 and p16 protein expression have no relationship with HPV infection in normal or cancerous esophagus.
|
28529620 |
2017 |
|
Human papilloma virus infection
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
<b>CONCLUSIONS:</b> These results suggest that hr-HPV types are not associated with the development of ESCC and that p53 and p16 protein expression have no relationship with HPV infection in normal or cancerous esophagus.
|
28529620 |
2017 |
|
Lung Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<b>Patients & methods:</b> Lung tumor tissue microarray (n = 163), immunohistochemical study of p16 and p53, and HPV <i>in-situ</i> hybridization were analyzed.
|
31157548 |
2019 |
|
Advanced Head and Neck Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
<b>Purpose:</b> FDG-PET adds to clinical factors, such tumor stage and p16 status, in predicting local (LF), regional (RF), and distant failure (DF) in poor prognosis locally advanced head and neck cancer (HNC) treated with chemoradiation.
|
31799173 |
2019 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
<b>Results:</b> p16 and p53 were detected in 50.7 and 57.3% of adenocarcinoma (ADCs; n = 75), and 35.2 and 63.6% of squamous cell carcinoma (n = 88).
|
31157548 |
2019 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Results:</b> p16 and p53 were detected in 50.7 and 57.3% of adenocarcinoma (ADCs; n = 75), and 35.2 and 63.6% of squamous cell carcinoma (n = 88).
|
31157548 |
2019 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
<i>K</i><sub>ep</sub> kurtosis and <i>V</i><sub>e</sub> min can differentiate p16 positive and p16 negative carcinomas.
|
30718984 |
2019 |
|
Papilloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<i>K</i><sub>ep</sub> kurtosis was significantly higher in p16 tumors, and <i>V</i><sub>e</sub> min was significantly lower in p16 tumors compared to the p16 negative tumors.
|
30718984 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<i>K</i><sub>ep</sub> kurtosis was significantly higher in p16 tumors, and <i>V</i><sub>e</sub> min was significantly lower in p16 tumors compared to the p16 negative tumors.
|
30718984 |
2019 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
(Cancer Res 55:2053-2055, 1995), which showed no p16 mutations or homozygous deletions in 18 primary neuroblastomas and nine tumor-derived cell lines.
|
9115582 |
1997 |
|
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
(Cancer Res 55:2053-2055, 1995), which showed no p16 mutations or homozygous deletions in 18 primary neuroblastomas and nine tumor-derived cell lines.
|
9115582 |
1997 |
|
Myeloid Leukemia
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
13 primary myeloid leukaemia samples had negligible levels of p16 mRNA.
|
7577621 |
1995 |
|
Seborrheic keratosis
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
16/23 SK showed strong to moderate p16 expression.
|
29375515 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
37/137 patients demonstrating moderate/strong p16(INK4A) expression relapsed (27.0%), as opposed to 10/16 (62.5%) with absent/weak staining (log rank test p<0.001). p16 and p53 expression were inversely correlated. p16(INK4A) negative tumours were more frequent in men. p16(INK4A) negative patients had significantly worse overall survival (p<0.001).
|
24021343 |
2013 |
|
Papilloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
45 studies were identified and included. p16 immunohistochemistry (IHC), HPV DNA in situ hybridization (ISH) and HPV polymerase chain reaction (PCR) are the commonest tests to determine HPV status. p16 IHC and HPV DNA PCR are highly sensitive whilst HPV DNA ISH is more specific, these techniques conventionally utilize surgical biopsies.
|
28285422 |
2017 |
|
Hepatocarcinogenesis
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
5'CpG islands methylation of p16 and p15 genes might be an early event in hepatocarcinogenesis.
|
15112341 |
2004 |
|
Oropharyngeal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
50 % is a reasonable cut-point for p16; HPV DNA positive/p16 negative OSCCs may be treated as HPV negative for clinical purposes; HPV DNA/p16 testing may add no prognostic information over p16 alone.
|
23208131 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
80% (28/35) of patient tumors had high p16 expression using conventional IHC.
|
25271758 |
2014 |
|
Malignant neoplasm of mouth
|
0.080 |
Biomarker
|
group |
BEFREE |
91.1% of the oropharynx cancer patients had p16 positive tumors compared to 3.3% of oral cavity cancer.
|
29312616 |
2017 |
|
Oral Cavity Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
91.1% of the oropharynx cancer patients had p16 positive tumors compared to 3.3% of oral cavity cancer.
|
29312616 |
2017 |
|
Coronary Arteriosclerosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
9p21.3 Coronary Artery Disease Risk Variants Disrupt TEAD Transcription Factor-Dependent Transforming Growth Factor β Regulation of p16 Expression in Human Aortic Smooth Muscle Cells.
|
26487755 |
2015 |